These results suggest that pharmacological inhibition of β-catenin can bypass MEK inhibitor resistance in PIK3CA mutant colon cancer cells and that this approach may be a potent combination therapeutic strategy. This evidence concerns the gene PIK3CA and malignant colon neoplasm.